{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:00:10Z","timestamp":1789531210612,"version":"build-2803163510"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100007622","name":"Bernische Krebsliga","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12931-017-0546-5","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T04:35:29Z","timestamp":1491971729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-054X","authenticated-orcid":false,"given":"Lourdes","family":"Cortes-Dericks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph Alexander","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,12]]},"reference":[{"key":"546_CR1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413\u20139.","journal-title":"Carcinogenesis"},{"key":"546_CR2","first-page":"70","volume":"12","author":"FE Mott","year":"2012","unstructured":"Mott FE. Mesothelioma: A Review. Ochsner J. 2012;12:70\u20139.","journal-title":"Ochsner J"},{"key":"546_CR3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","volume":"5","author":"DA Fennell","year":"2008","unstructured":"Fennell DA, Gaudino G, O\u2019Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008;5:136\u201347.","journal-title":"Nat Clin Pract Oncol"},{"key":"546_CR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/cancers2020523","volume":"2","author":"M Tomasetti","year":"2010","unstructured":"Tomasetti M, Santarelli L. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers. 2010;2:523\u201348.","journal-title":"Cancers"},{"key":"546_CR5","first-page":"52","volume":"51","author":"V Ascoli","year":"2015","unstructured":"Ascoli V. Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines. Ann DellIstituto Super Sanit\u00e0. 2015;51:52\u20139.","journal-title":"Ann DellIstituto Super Sanit\u00e0"},{"issue":"Suppl 4","key":"546_CR6","first-page":"S397","volume":"5","author":"K Porpodis","year":"2013","unstructured":"Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013;5 Suppl 4:S397\u2013406.","journal-title":"J Thorac Dis"},{"key":"546_CR7","first-page":"71","volume":"13","author":"N Nasreen","year":"2002","unstructured":"Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, et al. Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res. 2002;13:71\u20138.","journal-title":"Oncol Res"},{"key":"546_CR8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2014.10.007","volume":"41","author":"J Remon","year":"2015","unstructured":"Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41:27\u201334.","journal-title":"Cancer Treat Rev"},{"key":"546_CR9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","volume":"41","author":"V Panou","year":"2015","unstructured":"Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, R\u00f8e OD. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. 2015;41:486\u201395.","journal-title":"Cancer Treat Rev"},{"key":"546_CR10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/MCP.0b013e32832b98eb","volume":"15","author":"J Creaney","year":"2009","unstructured":"Creaney J, Robinson BWS. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med. 2009;15:366\u201370.","journal-title":"Curr Opin Pulm Med"},{"key":"546_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"546_CR12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","volume":"6","author":"NL Henry","year":"2012","unstructured":"Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6:140\u20136.","journal-title":"Mol Oncol"},{"key":"546_CR13","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1742-4658.2011.08071.x","volume":"278","author":"S Misra","year":"2011","unstructured":"Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011;278:1429\u201343.","journal-title":"FEBS J"},{"key":"546_CR14","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-09-0479","volume":"15","author":"BP Toole","year":"2009","unstructured":"Toole BP. Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res. 2009;15:7462\u20138.","journal-title":"Clin Cancer Res"},{"key":"546_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drup.2008.04.002","volume":"11","author":"BP Toole","year":"2008","unstructured":"Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance. Drug Resist Updat. 2008;11:110\u201321.","journal-title":"Drug Resist Updat"},{"key":"546_CR16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/mp.52.4.189","volume":"52","author":"S Goodison","year":"1999","unstructured":"Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol. 1999;52:189\u201396.","journal-title":"Mol Pathol"},{"key":"546_CR17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1022931016285","volume":"20","author":"S Jothy","year":"2003","unstructured":"Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis. 2003;20:195\u2013201.","journal-title":"Clin Exp Metastasis"},{"key":"546_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/B:HIJO.0000032354.94213.69","volume":"35","author":"R Marhaba","year":"2004","unstructured":"Marhaba R, Z\u00f6ller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211\u201331.","journal-title":"J Mol Histol"},{"key":"546_CR19","doi-asserted-by":"crossref","first-page":"e2087204","DOI":"10.1155\/2016\/2087204","volume":"2016","author":"R Thapa","year":"2016","unstructured":"Thapa R, Wilson GD, Thapa R, Wilson GD. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer, The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells Int. 2016;2016:e2087204.","journal-title":"Stem Cells Int"},{"key":"546_CR20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12013-014-9844-4","volume":"69","author":"J Wang","year":"2014","unstructured":"Wang J, Li Z, White J, Zhang L. Lung cancer stem cells and implications for future therapeutics. Cell Biochem Biophys. 2014;69:389\u201398.","journal-title":"Cell Biochem Biophys"},{"key":"546_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/CBM-140424","volume":"14","author":"R Roudi","year":"2014","unstructured":"Roudi R, Madjd Z, Korourian A, Mehrazma M, Molanae S, Sabet MN, et al. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer Biomark Sect Dis Markers. 2014;14:457\u201367.","journal-title":"Cancer Biomark Sect Dis Markers"},{"key":"546_CR22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-14-304","volume":"14","author":"L Cortes-Dericks","year":"2014","unstructured":"Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH (high) CD44 (+) phenotype and sphere-forming capacity. BMC Cancer. 2014;14:304.","journal-title":"BMC Cancer"},{"key":"546_CR23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/resp.12094","volume":"18","author":"M Alamgeer","year":"2013","unstructured":"Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: Evidence and controversies. Respirol Carlton Vic. 2013;18:757\u201364.","journal-title":"Respirol Carlton Vic"},{"key":"546_CR24","doi-asserted-by":"crossref","first-page":"e14062","DOI":"10.1371\/journal.pone.0014062","volume":"5","author":"EL-H Leung","year":"2010","unstructured":"Leung EL-H, Fiscus RR, Tung JW, Tin VP-C, Cheng LC, Sihoe AD-L, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010;5:e14062.","journal-title":"PLoS One"},{"key":"546_CR25","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/onc.2010.207","volume":"29","author":"A Eramo","year":"2010","unstructured":"Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene. 2010;29:4625\u201335.","journal-title":"Oncogene"},{"key":"546_CR26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5966\/sctm.2015-0048","volume":"4","author":"Y Yan","year":"2015","unstructured":"Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4:1033\u201343.","journal-title":"Stem Cells Transl Med"},{"key":"546_CR27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1054\/bjoc.2001.1922","volume":"85","author":"Y Li","year":"2001","unstructured":"Li Y, Heldin P. Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer. 2001;85:600\u20137.","journal-title":"Br J Cancer"},{"key":"546_CR28","doi-asserted-by":"crossref","first-page":"d604","DOI":"10.2741\/A305","volume":"3","author":"W Knudson","year":"1998","unstructured":"Knudson W. The role of CD44 as a cell surface hyaluronan receptor during tumor invasion of connective tissue. Front Biosci J Virtual Libr. 1998;3:d604\u2013615.","journal-title":"Front Biosci J Virtual Libr"},{"key":"546_CR29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/ard.54.5.429","volume":"54","author":"TC Laurent","year":"1995","unstructured":"Laurent TC, Laurent UB, Fraser JR. Functions of hyaluronan. Ann Rheum Dis. 1995;54:429\u201332.","journal-title":"Ann Rheum Dis"},{"key":"546_CR30","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1038\/icb.1996.32","volume":"74","author":"TC Laurent","year":"1996","unstructured":"Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996;74:A1\u20137.","journal-title":"Immunol Cell Biol"},{"key":"546_CR31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.resinv.2013.02.002","volume":"51","author":"N Fujimoto","year":"2013","unstructured":"Fujimoto N, Gemba K, Asano M, Fuchimoto Y, Wada S, Ono K, et al. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma. Respir Investig. 2013;51:92\u20137.","journal-title":"Respir Investig"},{"key":"546_CR32","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/1097-0142(19940301)73:5<1406::AID-CNCR2820730515>3.0.CO;2-I","volume":"73","author":"G Martensson","year":"1994","unstructured":"Martensson G, Thylen A, Lindquist U, Hjerpe A. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer. 1994;73:1406\u201310.","journal-title":"Cancer"},{"key":"546_CR33","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1378\/chest.94.5.1037","volume":"94","author":"T Pettersson","year":"1988","unstructured":"Pettersson T, Fr\u00f6seth B, Riska H, Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest. 1988;94:1037\u20139.","journal-title":"Chest"},{"key":"546_CR34","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/1097-0142(19870615)59:12<2104::AID-CNCR2820591224>3.0.CO;2-I","volume":"59","author":"T Frebourg","year":"1987","unstructured":"Frebourg T, Lerebours G, Delpech B, Benhamou D, Bertrand P, Maingonnat C, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer. 1987;59:2104\u20137.","journal-title":"Cancer"},{"key":"546_CR35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/1097-0142(19890701)64:1<68::AID-CNCR2820640112>3.0.CO;2-I","volume":"64","author":"IM Dahl","year":"1989","unstructured":"Dahl IM, Solheim OP, Erikstein B, M\u00fcller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer. 1989;64:68\u201373.","journal-title":"Cancer"},{"key":"546_CR36","first-page":"529","volume":"120","author":"H Arai","year":"1979","unstructured":"Arai H, Kang KY, Sato H, Satoh K, Nagai H, Motomiya M, et al. Significance of the quantification and demonstration of hyaluronic acid in tissue specimens for the diagnosis of pleural mesothelioma. Am Rev Respir Dis. 1979;120:529\u201332.","journal-title":"Am Rev Respir Dis"},{"key":"546_CR37","first-page":"46","volume":"26","author":"H Arai","year":"1979","unstructured":"Arai H. A study on acid glycosaminoglycans in pleural diseases. Sci Rep Res Inst Tohoku Univ Med. 1979;26:46\u201370.","journal-title":"Sci Rep Res Inst Tohoku Univ Med."},{"key":"546_CR38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10408360290795574","volume":"39","author":"D Naor","year":"2002","unstructured":"Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39:527\u201379.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"546_CR39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1083\/jcb.124.1.71","volume":"124","author":"CR Mackay","year":"1994","unstructured":"Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, G\u00fcnthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994;124:71\u201382.","journal-title":"J Cell Biol"},{"key":"546_CR40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/mp.51.4.191","volume":"51","author":"RJ Sneath","year":"1998","unstructured":"Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 1998;51:191\u2013200.","journal-title":"Mol Pathol"},{"key":"546_CR41","doi-asserted-by":"crossref","unstructured":"Karousou E, Misra S, Ghatak S, Dobra K, G\u00f6tte M, Vigetti D, et al. Roles and targeting of the HAS\/hyaluronan\/CD44 molecular system in cancer. Matrix Biol. 2017;59:3-22.","DOI":"10.1016\/j.matbio.2016.10.001"},{"key":"546_CR42","doi-asserted-by":"publisher","unstructured":"Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol. 2015;6. doi: 10.3389\/fimmu.2015.00201","DOI":"10.3389\/fimmu.2015.00201"},{"key":"546_CR43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/mp.50.2.57","volume":"50","author":"Z Rudzki","year":"1997","unstructured":"Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol. 1997;50:57\u201371.","journal-title":"Mol Pathol"},{"key":"546_CR44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0046-8177(97)90154-4","volume":"28","author":"TA Tran","year":"1997","unstructured":"Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol. 1997;28:809\u201314.","journal-title":"Hum Pathol"},{"key":"546_CR45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jtho.2016.10.023","volume":"12","author":"H Cho","year":"2017","unstructured":"Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, et al. Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-L1 in malignant pleural mesothelioma. J Thorac Oncol. 2017;12:477\u201390.","journal-title":"J Thorac Oncol"},{"key":"546_CR46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-13-69","volume":"13","author":"B Nuvoli","year":"2014","unstructured":"Nuvoli B, Germoni S, Morosetti C, Santoro R, Cortese G, Masi S, et al. Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. Mol Cancer. 2014;13:69.","journal-title":"Mol Cancer"},{"key":"546_CR47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2016.10.020","volume":"385","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis. Cancer Lett. 2017;385:215\u201324.","journal-title":"Cancer Lett"},{"key":"546_CR48","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1074\/jbc.275.3.1829","volume":"275","author":"LY Bourguignon","year":"2000","unstructured":"Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000;275:1829\u201338.","journal-title":"J Biol Chem"},{"key":"546_CR49","doi-asserted-by":"crossref","first-page":"d637","DOI":"10.2741\/A308","volume":"3","author":"LY Bourguignon","year":"1998","unstructured":"Bourguignon LY, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci. 1998;3:d637\u2013649.","journal-title":"Front Biosci"},{"key":"546_CR50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0065-230X(08)60101-3","volume":"71","author":"D Naor","year":"1997","unstructured":"Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241\u2013319.","journal-title":"Adv Cancer Res"},{"key":"546_CR51","doi-asserted-by":"crossref","first-page":"39703","DOI":"10.1074\/jbc.M204320200","volume":"277","author":"LYW Bourguignon","year":"2002","unstructured":"Bourguignon LYW, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem. 2002;277:39703\u201312.","journal-title":"J Biol Chem"},{"key":"546_CR52","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/sj.onc.1202447","volume":"18","author":"I Okamoto","year":"1999","unstructured":"Okamoto I, Kawano Y, Tsuiki H, Sasaki J, Nakao M, Matsumoto M, et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene. 1999;18:1435\u201346.","journal-title":"Oncogene"},{"key":"546_CR53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0002-9440(10)64863-8","volume":"160","author":"I Okamoto","year":"2002","unstructured":"Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol. 2002;160:441\u20137.","journal-title":"Am J Pathol"},{"key":"546_CR54","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1074\/jbc.M506740200","volume":"281","author":"KN Sugahara","year":"2006","unstructured":"Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861\u20138.","journal-title":"J Biol Chem"},{"key":"546_CR55","first-page":"4539","volume":"54","author":"SB Fox","year":"1994","unstructured":"Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994;54:4539\u201346.","journal-title":"Cancer Res"},{"key":"546_CR56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.freeradbiomed.2017.02.011","volume":"106","author":"SH Chew","year":"2017","unstructured":"Chew SH, Okazaki Y, Akatsuka S, Wang S, Jiang L, Ohara Y, et al. Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma. Free Radic Biol Med. 2017;106:91\u20139.","journal-title":"Free Radic Biol Med"},{"key":"546_CR57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fncel.2015.00175","volume":"9","author":"J Dzwonek","year":"2015","unstructured":"Dzwonek J, Wilczynski GM. CD44: molecular interactions, signaling and functions in the nervous system. Front Cell Neurosci. 2015;9:175.","journal-title":"Front Cell Neurosci"},{"issue":"Pt 3","key":"546_CR58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1242\/jcs.00954","volume":"117","author":"RF Thorne","year":"2004","unstructured":"Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci. 2004;117(Pt 3):373\u201380.","journal-title":"J Cell Sci"},{"key":"546_CR59","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1042\/bj2350903","volume":"235","author":"EA Balazs","year":"1986","unstructured":"Balazs EA, Laurent TC, Jeanloz RW. Nomenclature of hyaluronic acid. Biochem J. 1986;235:903.","journal-title":"Biochem J"},{"key":"546_CR60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.17221\/1930-VETMED","volume":"8","author":"J Necas","year":"2008","unstructured":"Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. Veterinari Medicina. 2008;8:397\u2013411.","journal-title":"Veterinari Medicina"},{"key":"546_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2005.05.006","volume":"237","author":"A Hill","year":"2006","unstructured":"Hill A, McFarlane S, Johnston PG, Waugh DJJ. The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett. 2006;237:1\u20139.","journal-title":"Cancer Lett"},{"key":"546_CR62","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1096\/fasebj.6.7.1563592","volume":"6","author":"TC Laurent","year":"1992","unstructured":"Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6:2397\u2013404.","journal-title":"FASEB J"},{"key":"546_CR63","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fonc.2015.00180","volume":"5","author":"T Chanmee","year":"2015","unstructured":"Chanmee T, Ontong P, Kimata K, Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front Oncol. 2015;5:180.","journal-title":"Front Oncol"},{"key":"546_CR64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/1319-3767.43274","volume":"14","author":"B Geramizadeh","year":"2008","unstructured":"Geramizadeh B, Janfeshan K, Saberfiroozi M. Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol. 2008;14:174\u20137.","journal-title":"Saudi J Gastroenterol"},{"key":"546_CR65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-5926-4-6","volume":"4","author":"P Halfon","year":"2005","unstructured":"Halfon P, Bourli\u00e8re M, P\u00e9naranda G, Deydier R, Renou C, Botta-Fridlund D, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol. 2005;4:6.","journal-title":"Comp Hepatol"},{"key":"546_CR66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2893.1998.00100.x","volume":"5","author":"VS Wong","year":"1998","unstructured":"Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998;5:187\u201392.","journal-title":"J Viral Hepat"},{"key":"546_CR67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2008.03.007","volume":"18","author":"LYW Bourguignon","year":"2008","unstructured":"Bourguignon LYW. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol. 2008;18:251\u20139.","journal-title":"Semin Cancer Biol"},{"key":"546_CR68","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc1391","volume":"4","author":"BP Toole","year":"2004","unstructured":"Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528\u201339.","journal-title":"Nat Rev Cancer"},{"key":"546_CR69","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.cellbio.23.090506.123337","volume":"23","author":"D Jiang","year":"2007","unstructured":"Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol. 2007;23:435\u201361.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"546_CR70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","volume":"4","author":"H Ponta","year":"2003","unstructured":"Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"546_CR71","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1074\/jbc.R100038200","volume":"277","author":"EA Turley","year":"2002","unstructured":"Turley EA, Noble PW, Bourguignon LYW. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277:4589\u201392.","journal-title":"J Biol Chem"},{"key":"546_CR72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4161\/sgtp.19110","volume":"3","author":"LYW Bourguignon","year":"2012","unstructured":"Bourguignon LYW. Hyaluronan-CD44 interaction promotes microRNA signaling and RhoGTPase activation leading to tumor progression. Small GTPases. 2012;3:53\u20139.","journal-title":"Small GTPases"},{"key":"546_CR73","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ejca.2010.02.024","volume":"46","author":"V Orian-Rousseau","year":"2010","unstructured":"Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271\u20137.","journal-title":"Eur J Cancer"},{"key":"546_CR74","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s13277-012-0473-5","volume":"33","author":"T Hanagiri","year":"2012","unstructured":"Hanagiri T, Shinohara S, Takenaka M, Shigematsu Y, Yasuda M, Shimokawa H, et al. Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. 2012;33:2135\u201341.","journal-title":"Tumour Biol"},{"key":"546_CR75","first-page":"4516","volume":"54","author":"T Asplund","year":"1994","unstructured":"Asplund T, Heldin P. Hyaluronan receptors Are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 1994;54:4516\u201323.","journal-title":"Cancer Res"},{"key":"546_CR76","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1309\/TWCQV536WWRNEU51","volume":"130","author":"S Cappia","year":"2008","unstructured":"Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol. 2008;130:58\u201364.","journal-title":"Am J Clin Pathol"},{"key":"546_CR77","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1172\/JCI12980","volume":"107","author":"DT Denhardt","year":"2001","unstructured":"Denhardt DT, Noda M, O\u2019Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055\u201361.","journal-title":"J Clin Invest"},{"key":"546_CR78","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/onc.2009.478","volume":"29","author":"K Tajima","year":"2010","unstructured":"Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010;29:1941\u201351.","journal-title":"Oncogene"},{"key":"546_CR79","first-page":"196","volume":"1","author":"MB Penno","year":"1995","unstructured":"Penno MB, Askin FB, Ma H, Carbone M, Vargas MP, Pass HI. High CD44 expression on human mesotheliomas mediates association with hyaluronan. Cancer J Sci Am. 1995;1:196\u2013203.","journal-title":"Cancer J Sci Am"},{"key":"546_CR80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1365-2559.1997.d01-590.x","volume":"30","author":"RL Attanoos","year":"1997","unstructured":"Attanoos RL, Webb R, Gibbs AR. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology. 1997;30:260\u20133.","journal-title":"Histopathology"},{"key":"546_CR81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/dc.20201","volume":"32","author":"AM Afify","year":"2005","unstructured":"Afify AM, Stern R, Michael CW. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol. 2005;32:145\u201350.","journal-title":"Diagn Cytopathol"},{"key":"546_CR82","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/JTO.0b013e3182a59f45","volume":"8","author":"G Al\u00ec","year":"2013","unstructured":"Al\u00ec G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, et al. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol. 2013;8:1389\u201395.","journal-title":"J Thorac Oncol"},{"key":"546_CR83","first-page":"1113","volume":"31","author":"K T\u00f6rr\u00f6nen","year":"2016","unstructured":"T\u00f6rr\u00f6nen K, Soini Y, P\u00e4\u00e4kk\u00f6 P, Parkkinen J, Sironen R, Rilla K. Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas. Histol Histopathol. 2016;31:1113\u201322.","journal-title":"Histol Histopathol"},{"key":"546_CR84","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JTO.0b013e318200f447","volume":"6","author":"JM Porcel","year":"2011","unstructured":"Porcel JM, Esquerda A, Rodriguez-Panadero F, Mart\u00ednez-Iribarren A, Bielsa S. The use of pleural fluid sCD44v6\/std ratio for distinguishing mesothelioma from other pleural malignancies. J Thorac Oncol. 2011;6:190\u20134.","journal-title":"J Thorac Oncol"},{"key":"546_CR85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0021-9258(18)73363-2","volume":"133","author":"K Meyer","year":"1940","unstructured":"Meyer K, Chaffee E. Hyaluronic acid in the pleural fluid associated with a malignant tumor involving the pleura and peritoneum. J Biol Chem. 1940;133:83\u201391.","journal-title":"J Biol Chem"},{"key":"546_CR86","first-page":"1850","volume":"45","author":"J Roboz","year":"1985","unstructured":"Roboz J, Greaves J, Silides D, Chahinian AP, Holland JF. Hyaluronic acid content of effusions as a diagnostic Aid for malignant mesothelioma. Cancer Res. 1985;45:1850\u20134.","journal-title":"Cancer Res"},{"key":"546_CR87","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/1097-0142(19841115)54:10<2195::AID-CNCR2820541021>3.0.CO;2-L","volume":"54","author":"B Chiu","year":"1984","unstructured":"Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WTE. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer. 1984;54:2195\u20139.","journal-title":"Cancer"},{"key":"546_CR88","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.0.CO;2-N","volume":"86","author":"A Thyl\u00e9n","year":"1999","unstructured":"Thyl\u00e9n A, Wallin J, Martensson G. Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma. Cancer. 1999;86:2000\u20135.","journal-title":"Cancer"},{"key":"546_CR89","first-page":"6118","volume":"49","author":"J Klominek","year":"1989","unstructured":"Klominek J, Rob\u00e9rt K-H, Hjerpe A, Wickstr\u00f6m B, Gahrton G. Serum-dependent growth patterns of Two, newly established human mesothelioma cell lines. Cancer Res. 1989;49:6118\u201322.","journal-title":"Cancer Res"},{"key":"546_CR90","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00000478-199202000-00003","volume":"16","author":"N Azumi","year":"1992","unstructured":"Azumi N, Underhill CB, Kagan E, Sheibani K. A novel biotinylated probe specific for hyaluronate. Its diagnostic value in diffuse malignant mesothelioma. Am J Surg Pathol. 1992;16:116\u201321.","journal-title":"Am J Surg Pathol"},{"key":"546_CR91","first-page":"428","volume":"22","author":"A Boersma","year":"1975","unstructured":"Boersma A, Degand P, Biserte G, Havez R. Report on the study of hyaluronic acid in the diagnosis of pleural mesotheliomas: study of 100 hyaluronic acid rich effusions. Biomedicine. 1975;22:428\u201332.","journal-title":"Biomedicine"},{"key":"546_CR92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jjco\/27.5.293","volume":"27","author":"S Atagi","year":"1997","unstructured":"Atagi S, Ogawara M, Kawahara M, Sakatani M, Furuse K, Ueda E, et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol. 1997;27:293\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"546_CR93","first-page":"146","volume":"49","author":"W Matzel","year":"1979","unstructured":"Matzel W, Schubert G. Hyaluronic acid in pleural fluids: an additional parameter for clinical diagnosis on diffuse mesotheliomas (author\u2019s transl). Arch Geschwulstforsch. 1979;49:146\u201354.","journal-title":"Arch Geschwulstforsch"},{"key":"546_CR94","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/1097-0142(197907)44:1<221::AID-CNCR2820440136>3.0.CO;2-O","volume":"44","author":"B Waxler","year":"1979","unstructured":"Waxler B, Eisenstein R, Battifora H. Electrophoresis of tissue glycosaminoglycans as an aid in the diagnosis of mesotheliomas. Cancer. 1979;44:221\u20137.","journal-title":"Cancer"},{"key":"546_CR95","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1097-0142(19850801)56:3<567::AID-CNCR2820560325>3.0.CO;2-7","volume":"56","author":"T Kawai","year":"1985","unstructured":"Kawai T, Suzuki M, Shinmei M, Maenaka Y, Kageyama K. Glycosaminoglycans in malignant diffuse mesothelioma. Cancer. 1985;56:567\u201374.","journal-title":"Cancer"},{"key":"546_CR96","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1097-0142(19860101)57:1<106::AID-CNCR2820570122>3.0.CO;2-C","volume":"57","author":"T Nakano","year":"1986","unstructured":"Nakano T, Fujii J, Tamura S, Amuro Y, Nabeshima K, Horai T, et al. Glycosaminoglycan in malignant pleural mesothelioma. Cancer. 1986;57:106\u201310.","journal-title":"Cancer"},{"key":"546_CR97","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00428-007-0375-x","volume":"450","author":"L Welker","year":"2007","unstructured":"Welker L, M\u00fcller M, Holz O, Vollmer E, Magnussen H, J\u00f6rres RA. Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007;450:455\u201361.","journal-title":"Virchows Arch"},{"key":"546_CR98","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/1097-0142(19910501)67:9<2410::AID-CNCR2820670933>3.0.CO;2-D","volume":"67","author":"G Hillerdal","year":"1991","unstructured":"Hillerdal G, Lindqvist U, Engstr\u00f6m-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer. 1991;67:2410\u20134.","journal-title":"Cancer"},{"key":"546_CR99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0215(19960729)67:3<393::AID-IJC2910670302>3.0.CO;2-Y","volume":"67","author":"P Teder","year":"1996","unstructured":"Teder P, Versnel MA, Heldin P. Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells. Int J Cancer. 1996;67:393\u20138.","journal-title":"Int J Cancer"},{"key":"546_CR100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.21037\/tlcr.2016.02.01","volume":"5","author":"G Hardavella","year":"2016","unstructured":"Hardavella G, George R, Sethi T. Lung cancer stem cells\u2014characteristics, phenotype. Transl Lung Cancer Res. 2016;5:272\u20139.","journal-title":"Transl Lung Cancer Res"},{"key":"546_CR101","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","volume":"11","author":"M Z\u00f6ller","year":"2011","unstructured":"Z\u00f6ller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254\u201367.","journal-title":"Nat Rev Cancer"},{"key":"546_CR102","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/1535370213480714","volume":"238","author":"K Williams","year":"2013","unstructured":"Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre) metastatic niches. Exp Biol Med. 2013;238:324\u201338.","journal-title":"Exp Biol Med"},{"key":"546_CR103","doi-asserted-by":"crossref","first-page":"e57020","DOI":"10.1371\/journal.pone.0057020","volume":"8","author":"P Wang","year":"2013","unstructured":"Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One. 2013;8:e57020.","journal-title":"PLoS One"},{"key":"546_CR104","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/carcin\/bgr127","volume":"32","author":"C Frei","year":"2011","unstructured":"Frei C, Opitz I, Soltermann A, Fischer B, Moura U, Rehrauer H, et al. Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis. 2011;32:1324\u201332.","journal-title":"Carcinogenesis"},{"key":"546_CR105","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2010.12.054","volume":"404","author":"FI Ghani","year":"2011","unstructured":"Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, et al. Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun. 2011;404:735\u201342.","journal-title":"Biochem Biophys Res Commun"},{"key":"546_CR106","first-page":"437","volume":"37","author":"L Cortes-Dericks","year":"2010","unstructured":"Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int J Oncol. 2010;37:437\u201344.","journal-title":"Int J Oncol"},{"key":"546_CR107","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3978\/j.issn.2305-5839.2015.07.03","volume":"3","author":"W Zhang","year":"2015","unstructured":"Zhang W, Wu X, Wu L, Zhang W, Zhao X. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med. 2015;3:182. doi: 10.3978\/j.issn.2305-5839.2015.07.03 .","journal-title":"Ann Transl Med"},{"key":"546_CR108","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/bjc.2011.104","volume":"104","author":"S Bij van der","year":"2011","unstructured":"van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BAJM, Moons KGM. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 2011;104:1325\u201333.","journal-title":"Br J Cancer"},{"key":"546_CR109","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1378\/chest.111.1.106","volume":"111","author":"AA Renshaw","year":"1997","unstructured":"Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106\u20139.","journal-title":"Chest"},{"key":"546_CR110","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.rmed.2006.08.026","volume":"101","author":"SV Fletcher","year":"2007","unstructured":"Fletcher SV, Clark RJ. The Portsmouth thoracoscopy experience, an evaluation of service by retrospective case note analysis. Respir Med. 2007;101:1021\u20135.","journal-title":"Respir Med"},{"key":"546_CR111","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.legalmed.2007.06.001","volume":"10","author":"A Fassina","year":"2008","unstructured":"Fassina A, Fedeli U, Corradin M, Da Fr\u00e8 M, Fabbris L. Accuracy and reproducibility of pleural effusion cytology. Leg Med. 2008;10:20\u20135.","journal-title":"Leg Med"},{"key":"546_CR112","doi-asserted-by":"publisher","first-page":"e72030","DOI":"10.1371\/journal.pone.0072030","volume":"8","author":"F Mundt","year":"2013","unstructured":"Mundt F, Nilsonne G, Arslan S, Cs\u00fcr\u00f6s K, Hillerdal G, Yildirim H, et al. Hyaluronan and N-ERC\/mesothelin as Key biomarkers in a specific Two-step model to predict pleural malignant mesothelioma. PLoS ONE. 2013;8:e72030. doi: 10.1371\/journal.pone.0072030 .","journal-title":"PLoS ONE"},{"key":"546_CR113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13665-015-0106-8","volume":"4","author":"J Creaney","year":"2015","unstructured":"Creaney J, Dick IM, Robinson BWS. Discovery of new biomarkers for malignant mesothelioma. Curr Pulmonol Rep. 2015;4:15\u201321.","journal-title":"Curr Pulmonol Rep"},{"key":"546_CR114","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","volume":"362","author":"BWS Robinson","year":"2003","unstructured":"Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet Lond Engl. 2003;362:1612\u20136.","journal-title":"Lancet Lond Engl"},{"key":"546_CR115","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1078-0432.CCR-07-1613","volume":"14","author":"K Shiomi","year":"2008","unstructured":"Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, et al. Sensitive and specific New enzyme-linked immunosorbent assay for N-ERC\/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res. 2008;14:1431\u20137.","journal-title":"Clin Cancer Res"},{"key":"546_CR116","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/09031936.00226111","volume":"41","author":"I Pantazopoulos","year":"2013","unstructured":"Pantazopoulos I, Boura P, Xanthos T, Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013;41:706\u201315.","journal-title":"Eur Respir J"},{"key":"546_CR117","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","volume":"3","author":"J Creaney","year":"2008","unstructured":"Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol. 2008;3:851\u20137.","journal-title":"J Thorac Oncol"},{"key":"546_CR118","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF03256303","volume":"12","author":"L Greillier","year":"2008","unstructured":"Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther. 2008;12:375\u201390.","journal-title":"Mol Diagn Ther"},{"key":"546_CR119","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/thx.2006.076612","volume":"62","author":"YCG Lee","year":"2007","unstructured":"Lee YCG. Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer? Thorax. 2007;62:561\u20132.","journal-title":"Thorax"},{"key":"546_CR120","doi-asserted-by":"crossref","first-page":"21984","DOI":"10.1074\/jbc.270.37.21984","volume":"270","author":"T Kojima","year":"1995","unstructured":"Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984\u201390.","journal-title":"J Biol Chem"},{"key":"546_CR121","first-page":"31","volume":"71","author":"BD Grigoriu","year":"2009","unstructured":"Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis. 2009;71:31\u20138.","journal-title":"Monaldi Arch Chest Dis"},{"key":"546_CR122","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCP.0b013e32812144bb","volume":"13","author":"A Scherpereel","year":"2007","unstructured":"Scherpereel A, Lee YCG. Biomarkers for mesothelioma. Curr Opin Pulm Med. 2007;13:339\u2013443.","journal-title":"Curr Opin Pulm Med"},{"key":"546_CR123","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","volume":"367","author":"HI Pass","year":"2012","unstructured":"Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367:1417\u201327.","journal-title":"N Engl J Med"},{"key":"546_CR124","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","volume":"69","author":"J Creaney","year":"2014","unstructured":"Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014;69:895\u2013902.","journal-title":"Thorax"},{"key":"546_CR125","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","volume":"82","author":"J Creaney","year":"2013","unstructured":"Creaney J, Dick IM, Segal A, Musk AW, Robinson BWS. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013;82:491\u20138.","journal-title":"Lung Cancer"},{"key":"546_CR126","doi-asserted-by":"publisher","unstructured":"Creaney J, Robinson BWS. Malignant mesothelioma biomarkers - from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment. Chest. 2016; pii: S0012-3692(16)62593-X .DOI: 10.1016\/j.chest.2016.12.004 .","DOI":"10.1016\/j.chest.2016.12.004"},{"key":"546_CR127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/07357907.2012.749265","volume":"31","author":"PA Canessa","year":"2013","unstructured":"Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest. 2013;31:43\u201350.","journal-title":"Cancer Invest"},{"key":"546_CR128","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","volume":"30","author":"K Hollevoet","year":"2012","unstructured":"Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30:1541\u20139.","journal-title":"J Clin Oncol"},{"key":"546_CR129","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.clinbiochem.2009.03.007","volume":"42","author":"B Grigoriu","year":"2009","unstructured":"Grigoriu B, Chahine B, Zerimech F, Gr\u00e9goire M, Balduyck M, Copin M-C, et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem. 2009;42:1046\u201350.","journal-title":"Clin Biochem"},{"key":"546_CR130","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.07-0013","volume":"132","author":"J Creaney","year":"2007","unstructured":"Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007;132:1239\u201346.","journal-title":"Chest"},{"key":"546_CR131","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.lungcan.2007.08.030","volume":"59","author":"MM Heuvel van den","year":"2008","unstructured":"van den Heuvel MM, Korse CM, Bonfrer JMG, Baas P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer. 2008;59:350\u20134.","journal-title":"Lung Cancer"},{"key":"546_CR132","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31828f696b","volume":"8","author":"T Muley","year":"2013","unstructured":"Muley T, Dienemann H, Herth FJF, Thomas M, Meister M, Schneider J. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer. J Thorac Oncol. 2013;8:947\u201351.","journal-title":"J Thorac Oncol"},{"key":"546_CR133","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","volume":"13","author":"B-D Grigoriu","year":"2007","unstructured":"Grigoriu B-D, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928\u201335.","journal-title":"Clin Cancer Res"},{"key":"546_CR134","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","volume":"192","author":"M Bayram","year":"2014","unstructured":"Bayram M, Dongel I, Akba\u015f A, Benli \u0130, Akkoyunlu ME, Bakan ND. Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos. Lung. 2014;192:197\u2013203.","journal-title":"Lung"},{"key":"546_CR135","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1378\/chest.08-2665","volume":"136","author":"M Ray","year":"2009","unstructured":"Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888\u201396.","journal-title":"Chest"},{"key":"546_CR136","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","volume":"10","author":"HI Pass","year":"2004","unstructured":"Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004;10:849\u201359.","journal-title":"Clin Cancer Res"},{"key":"546_CR137","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-06-1027","volume":"12","author":"AJ Holloway","year":"2006","unstructured":"Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BWS, Lake RA, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res. 2006;12:5129\u201335.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"546_CR138","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.lungcan.2005.03.018","volume":"49","author":"GJ Gordon","year":"2005","unstructured":"Gordon GJ. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer. 2005;49 Suppl 1:S99\u2013103.","journal-title":"Lung Cancer"},{"key":"546_CR139","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.arbres.2014.06.005","volume":"51","author":"FR Panadero","year":"2015","unstructured":"Panadero FR. Diagnosis and Treatment of Malignant Pleural Mesothelioma. Arch Bronconeumol Engl Ed. 2015;51:177\u201384.","journal-title":"Arch Bronconeumol Engl Ed"},{"issue":"Supplement 5","key":"546_CR140","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdq173","volume":"21","author":"RA Stahel","year":"2010","unstructured":"Stahel RA, Weder W, Lievens Y, Felip E. On behalf of the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Supplement 5):v126\u20138.","journal-title":"Ann Oncol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-017-0546-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T11:58:00Z","timestamp":1658923080000},"score":1,"resource":{"primary":{"URL":"http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-017-0546-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,12]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1186\/s12931-017-0546-5","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,12]]},"article-number":"58"}}